human pulmonary artery endothelial cells  (Cell Applications Inc)

Journal: Nature Communications

Article Title: Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin

doi: 10.1038/s41467-025-68199-x

Figure Lengend Snippet: a Endothelial cells were isolated from murine lungs and subjected to bulk RNA sequencing. Created in BioRender. Brabenec, L. ( https://BioRender.com/mpa96bi ) b MDA plot showing DEGs in color that were more than 2-fold differentially regulated ( p < 0.05) in mice after cecal ligation and puncture (CLP) vs. mice subjected to laparotomy only (sham). Limma uses an empirical Bayes shrinkage method to moderate the standard errors of the estimated log-fold changes, which includes t-tests foreach gene To control for multiple testing the Benjamini and Hochberg method was used. c Principal component analysis of normalized expression values for n = 6 mice/group 18 h after sepsis induction. d Volcano plot representing DEGs in color and labelling of the 10 most up- and down-regulated genes in murine pulmonary endothelium. Limma uses an empirical Bayes shrinkage method to moderate the standard errors of the estimated log-fold changes, which includes t-tests foreach gene To control for multiple testing the Benjamini and Hochberg method was used. e List of the 10 most up- and down-regulated genes including the procalcitonin encoding gene Calca . f Up- and ( g ) down-regulated pathways in murine endothelium in response to polymicrobial sepsis. Enrichment analysis, statistical significance was assessed using adjusted p values (FDR correction) to account for multiple testing. h VEGFa and VEGFc is downregulated in isolated murine pulmonary endothelial cells 18 h after injection of human procalcitonin in mice, n = 3. i Human pulmonary microvascular endothelial cells show increased Calca expression after treatment with sepsis patients serum. This could be abolished by the use of procalcitonin antibody, n = 4 (Healthy), n = 5 (Sepsis), p = 0.0427. j , k Calcrl and Ramp1 show no difference in gene expression, n = 4 (Healthy), n = 5 (Sepsis), p = 0.0035. l VEGFa was downregulated in human pulmonary microvascular endothelial cells when treated with serum of septic patients, n = 4 (Healthy), n = 5 (Sepsis), p = 0.0047. m Expression of genes from LPS-treated human cells in our CLP study. We then took the top 50 up-regulated DEGs from the 8 h LPS study and found that 36 of these were also annotated in our dataset. Mean expression values for these genes from our study were calculated per group and then presented as heatmap with values scaled by row. Cluster 1: All genes in this cluster were up-regulated upon CLP as for LPS 8 h, and almost all DEGs (except ICAM1 ) were reduced in expression after AB treatment. Cluster 2: Genes in this cluster were down-regulated in our dataset upon CPL, but not up-regulated as in the LPS study. Of note, these DEGs were stronger down-regulated after AB treatment. One LPS-DEG gene, VCAM1 , was also up-regulated after CLP, but expressed higher in AB-treated samples compared to non-AB-treated CLP controls. Unpaired t test, data presented as mean ± SEM. p values as indicated. Source data are provided as a Source Data file.

Article Snippet: Human pulmonary endothelial cells (PromoCell) were cultured in cell culture media and exposed to serum from human sepsis patients diluted 1:1 in serum-free media.

Techniques: Isolation, RNA Sequencing, Ligation, Control, Expressing, Injection, Gene Expression

Journal: Nature Communications

Article Title: Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin

doi: 10.1038/s41467-025-68199-x

Figure Lengend Snippet: a , b Representative immunoblot and quantitative summary showing phosphorylated VE-cadherin at tyrosine residue 685 in murine endothelial cell lysates after stimulation with septic mice plasma for 15, 30 and 60 min, n = 4 (60), n = 5(ctrl,15,30) independent experiments/group, timesfold vs. control. Samples derive from the same experiment and blots were processed in parallel. Uncropped blots in Source Data. c Procalcitonin plasma concentrations during the course of sepsis in mice, n = 5 (CLP12h, 6 h), n = 12 (sham), n = −18 (CLP18h). d Schematic depicting the strategy of antibody generation targeting murine truncated procalcitonin. Created in BioRender. Brabenec, L. ( https://BioRender.com/7xr1vmf ) e Representative immunoblot showing phosphorylated VE-cadherin at tyrosine residue 685 in endothelial cell lysates 30 min after exposure to recombinant procalcitonin, n = 7, timesfold vs. control. Samples derive from the same experiment and blots were processed in parallel.Uncropped blots in Source Data. f Fluorescence-labeled macromolecule permeability of murine pulmonary endothelial cells exposed to septic mice’s plasma after pre-treatment with 1 µg of the antibody directed against truncated procalcitonin (PCT AB) and respective IgG control for two h, n = 48 (ctrl AB), n = 7 (ctrl IgG), n = 8 (Sepsis IgG, Sepsis AB). Data presented as mean ± SEM. One-way ANOVA/Bonferroni. p values as indicatedSource data are provided as a Source Data file.

Article Snippet: Human pulmonary endothelial cells (PromoCell) were cultured in cell culture media and exposed to serum from human sepsis patients diluted 1:1 in serum-free media.

Techniques: Western Blot, Residue, Clinical Proteomics, Control, Recombinant, Fluorescence, Labeling, Permeability

Journal: Nature Communications

Article Title: Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin

doi: 10.1038/s41467-025-68199-x

Figure Lengend Snippet: a Summary of the number of up- (red) and down-(blue) differentially regulated genes (DEGs) in murine endothelial cells. Results are derived from relating sham AB to sham IgG [left column], CLP IgG to sham IgG, CLP AB to CLP IgG and CLP AB to sham AB, respectively. b VENN diagram deciphering the number of DEGs from the same contrasts. c Scatter plot of genes showing mean log 2 fold differences of CLP controls and CLP AB treated mice to the respective sham-treated controls. For this comparison, the up-regulated genes of the cytokine-mediated signaling pathway were used that were commonly up-regulated DEGs in CLP IgG and CLP AB treated versus the respective sham controls. d Heatmap of expression levels of DEGs from all contrasts. Values were scaled by row. red: up-regulated DEGs, blue: down-regulated DEGs. Each column represents one mouse. e Expression differences in Il17 pathway. Colors represent differences in normalized expression levels from the strongest CLP AB responder (sample CLP_PCT_AB_11_02) versus a strong CLP IgG responder (sample CLP_IgG_ctrl_16_07) projected on the mouse IL-17 signaling pathway (KEGG pathway mmu04657). f Inhibition of procalcitonin activation by DPP4 inhibitor sitagliptin and blocking procalcitonins receptor by the PCTR antagonist olcegepant, reduced IL-17 plasma levels in septic mice. n = 7 (Sham IgG, CLP PCTAB), n = 6 (CLP IgG), n = 5 (PCTS Antagonist, DPP4 Inhibitor), timesfold vs. control. g Heatmap showing cytokine and chemokine expression profiles in murine blood 18 h after sepsis induction by cecal ligation and puncture (CLP)/control (sham) surgery following injection of the antibody and respective control IgG 6 h after surgery, data shown as ng/mL, n = 7 mice/group. Data is presented as mean ± SEM. One- and Two-way ANOVA and Bonferroni-correction. p values as indicated.Source data are provided as a Source Data file.

Article Snippet: Human pulmonary endothelial cells (PromoCell) were cultured in cell culture media and exposed to serum from human sepsis patients diluted 1:1 in serum-free media.

Techniques: Derivative Assay, Comparison, Expressing, Inhibition, Activation Assay, Blocking Assay, Clinical Proteomics, Control, Ligation, Injection

Journal: PLOS One

Article Title: In vitro and in vivo characterization of wild type BMP9 and a non-osteogenic variant in models of pulmonary arterial hypertension

doi: 10.1371/journal.pone.0329089

Figure Lengend Snippet: (A) WT BMP9 and A347E variant in cell-based human MSC assay measuring SP7 expression as a marker for osteogenic differentiation in a dose-response experiment (0.0195nM-10nM). (B) pSMAD1 activation in human endothelial cells in a dose-response experiment (0.000169nM-10nM). (C-E) Human primary pulmonary artery endothelial cells were treated with WT BMP9 and A347E variant at 10nM for 24h and gene expression was measured using Taqman PCR (C) ID2, (D) TGFBI, (E) PAI1. (F) pSMAD1 activation in primary rat endothelial cells in a dose-response experiment (0.000169nM-10nM). (G) WT BMP9 and A347E variant (30 µg/kg) were dosed SC to naïve rats (n = 4-5). Lung tissue was harvested 6h post dose and SMAD7 expression was evaluated in lung tissue as a PD marker by Taqman PCR. (H) WT BMP9 (30 µg/kg; IV) and A347E variant (1, 10, 30, 100 µg/kg; SC) was dosed to cynos (n = 3). Lung tissue was harvested 6h post dose and SMAD7 expression was evaluated in lung tissue as a PD marker by Taqman PCR.

Article Snippet: Human pulmonary artery endothelial cells, hPAEC (Cell Applications) were treated with WT BMP9 (R&D Systems) or BMP9-A347E at a single dose of 10nM for 24h.

Techniques: Variant Assay, Expressing, Marker, Activation Assay, Gene Expression